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INTRODUCTION
Globus pharyngeus (GP), a constant or intermittent perception
of a lump or a foreign body in the throat, is a common chief com-
plaint in the otolaryngologist’s office and one of the symptoms of
laryngopharyngeal reflux disease (LPRD) (1). Since proton pump
inhibitors (PPIs) have been accepted as the standard treatment for
LPRD (2), they are proved effective in controlling GP, and it is con-
sidered that there is causal relationship between LPRD and GP. On
the other hand, rikkunshito, a traditional Japanese medicine that
stimulates gastrointestinal movements is used as prokinetic to
treat the symptoms of gastroesophageal reflux disease (GERD)
(3). It was reported that adding prokinetic agents that accelerate
gastric emptying to PPIs improved symptoms of LPRD in the pa-
tients refractory to the standard PPI therapy (4).
In the present study, in order to clarify the prevalence of LPRD
in patients complaining of GP, an attempt was made to examine the
efficacy of the combination of rabeprazole, a PPI with rikkunshito
in controlling this sensation. We first examined the efficacy of ra-
beprazole alone in patients with GP. In the patients who did not
respond to rabeprazole, the efficacy of rabeprazole in combination
with rikkunshito was then examined. Finally we examined whether
the initial symptoms and endoscopic findings evaluated with a modi-
fied laryngopharyngeal reflux symptom index (RSI) (5, 6), and the
pre-treatment laryngopharyngeal reflux finding scores (RFS) (7)
could predict the efficacy of a PPI in combination with rikkunshito.
PATIENTS AND METHODS
Patients
The present study includes 106 patients (41 males and 65 fe-
males ; mean age : 62.514.1 years, range : 21-87 years old) com-
plaining of GP. They did not have any findings as glottic/subglottic
stenosis, carcinoma, leukoplakia or paradoxical vocal fold motion
to examination with a video rhinolaryngoscope system equipped
with a flexible fiber optic endoscope of 3.1 -mm-diameter (VNL-
100s, Pentax, Japan). This study was approved by the Committee
for Medical Ethics of Kochi National Hospital, Kochi Red Cross
Hospital and JA Kochi Hospital, and an informed consent was ob-
tained from each patient prior to the study.
Study design
All patients were first treated with rabeprazole alone at a dose
of 20 mg/day for 4 weeks. Respondents continued to be treated
with the same regimen for additional 4 weeks. Non-respondents
then treated with a combination of rabeprazole at the same dose,
and rikkunshito at a dose of 7.5 g/day for additional 4 weeks.
Evaluation
The feeling of GP was evaluated by visual analogue scale (VAS)
ranging from 0, no symptom to 100, presence of symptom at the
first visit. VAS scores were then measured 2, 4 and 8 weeks after
the treatment. The efficacy of the treatment on the symptom of
GP was determined in patients with more than 50% reduction in
VAS (8).
Before the treatment, the initial laryngopharyngeal symptoms
and endoscopic findings were evaluated with a modified RSI and
RFS. Belasfsky et al. developed RSI, a nine- item questionnaire for
assessment of symptoms in patients with LPRD (5). It was modified
to a four- item questionnaire by Oritate et al., which is usually used
clinically in Japan (6) (Table 1). RFS was also developed by Belasfsky
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et al. to evaluate eight endoscopic findings that are commonly ob-
served in patients with LPRD (7) (Table 2). The video- images of
laryngopharynx were recorded by the video rhinolaryngoscope
system with a flexible fiber optic endoscope of 3.1 -mm-diameter
(VNL-100s, Pentax, Japan). They were then evaluated by another
otolaryngologist blind to clinical data and independent from the ex-
aminer. A total RFS score of 7 or more was considered positive.
Statistics
Wilcoxon signed-ranks test were used for statistical analysis
with Statcel 3 and p0.05 was considered significant.
RESULTS
A hundred and six patients complaining of GP were first admin-
istrated with rabeprazole alone at a dose of 20 mg/day. The symp-
tom of GP improved in 45 patients (42.5%) after treatment for two
weeks and in 65 patients (61.3%) for four weeks. All these patients
received an additional 4-week administration of rabeprazole with
a lasting improvement of their symptom. The remaining 41 patients
were considered to have rabeprazole-refractory GP. Among them,
22 patients were administrated rabeprazole at the same dose in
combination with rikkunshito at a dose of 7.5 g/day and 19 who
refused further treatment dropped out. Four weeks after the com-
bination therapy, the symptom of GP was improved in 14 of 22 pa-
tients. Accordingly, a total of 79 patients (74.5%) responded to either
PPI therapy alone or to the combination of PPI and rikkunshito
(Fig.1).
The initial value of the modified RSI was 5.574.07 in the 79
patients who responded to either PPI therapy alone or to its combi-
nation with rikkunshito. It was similar to the RSI value of 6.00
10.84 in the 8 patients who were refractory to both therapies. Among
the 79 patients who responded to either PPI therapy alone or to its
combination with rikkunshito, the initial endoscopic findings were
evaluated using RFS in 60 patients and 3 patients showed positive
RFS. Among the 8 patients who did not respond to both therapies,
the initial endoscopic findings were evaluated using RFS in 6 pa-
tients and a patient showed positive RFS.
DISCUSSION
LPRD is caused by retrograde flow of acidic gastric contents via
esophagus into the larynx, and PPI is generally accepted as the
standard treatment for LPRD (1, 2). Moreover, it was reported that
higher dose PPI therapy for longer period was more effective in
patients with LPRD (9). Because GP is a common symptoms of
LPRD, in the present study, PPI therapy with rabeprazole at a high
dose of 20 mg/day was administrated in patients complaining of
GP and 61% of them showed improvement of the symptom 4 to 8
weeks later. The finding suggests that in more than half of patients
complaining of GP, the underlying cause is LPRD. This observa-
tion is indicative of a high prevalence of LPRD in patients com-
plaining of GP.
Prokinetic agents that stimulate anterograde movements through
the gastrointestional tract is used to treat the symptoms of GERD
(10). It was also reported that an addition of prokinetic agents to
PPI therapy improved symptoms of LPRD in patients who were
refractory to the standard PPI therapy (4). Therefore, it is sug-
gested that in addition to excessive acid reflux, dysmotility of the
esophagogastrointestional tract is involved in the pathophysiology
of LPRD. Because rikkunshito enhances gastroesophageal clear-
ance (11), it is used for the treatment of PPI-refractory patients
with both GERD and LPRD (3, 12). In the present study, 14 of 22
PPI-refractory patients complaining of GP responded to the com-
bination therapy of high dose rabeprazole with rikkunshito. This
finding suggests that gastroesophageal dysmotility is also involved
in the development of GP. But, in the remaining patients who were
refractory to both PPI alone and the combination therapy of PPI
with rikkunshito, their GP may be caused by psychiatric disease,
allergies or postnasal drip.
Several studies showed only a weak correlation between LPRD-
like laryngopharyngeal symptoms, endoscopic findings, hypopha-
ryngeal pH monitoring (13, 14). This is the reason why patients
initially diagnosed as LPRD based on their symptoms and signs,
often do not respond to PPI therapy. In fact, it was reported that
no pretherapeutic predictors of response to high dose PPI therapy
Table 1 Laryngopharyngeal Reflux Symptom Scores
Within the last month, how did the following problems affect you?
0=no problem 5=severe problem
1. Clearing your throat or an annoying cough 0 1 2 3 4 5
2. Hoarseness or a problem with your voice 0 1 2 3 4 5
3. Sensation of something sticking in your throat or a lump in your throat
Difficulty swallowing food, liquids , or pills
0 1 2 3 4 5
4. Heartburn, chest pain, indigestion, or stomach acid reflux 0 1 2 3 4 5
Table 2 Reflux Finding Score (RFS)
Reflux Finding Score (RFS)
subglottic 0=absent
2=present
Ventricular 0=partial
2=copmplete
Erythema/hyperemia 2=arytenoids only
4=diffuse
Vocal fold edema 1=mild
2=moderate
3=severe
4=polypoid
Diffuse laryngeal edema 1=mild
2=moderate
3=severe
4=obstructing
Posterior commissure hypertrophy 1=mild
2=moderate
3=severe
4=obstructing
Granuloma/granulation tissue 0=absent
2=present
Thick endolaryngeal mucus 0=absent
2=present
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such as symptoms, pH monitoring or esophageal manometry was
identified in patients with LPRD (9). The present study shows that
in patients complaining of GP, the pretherapeutic value of a modi-
fied RSI or positive RFS also did not predict the efficacy of PPI alone
or in combination with rikkunshito.
In conclusion, the present study suggests a high prevalence of
LPRD in patients complaining of globus pharyngeus. Because the
response to PPI therapy was unpredictable with neither laryngo-
pharyngeal symptoms nor endoscopic findings, we propose that
patients complaining of GP should be first treated with high dose
PPI therapy for more than 4 weeks. We also propose that in case
of PPI-refractory GP, patients should be then treated with the com-
bination therapy of high dose PPI with rikkunshito.
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Fig. 1 : Disposition flow chart showing the number of responder or non-responder patients complaining of globus pharyngeus to PPI therapy with
rabeprazole at a dose of 20 mg/day or to combination therapy of rabeprazole at a dose of 20 mg/day with rikkunshito at a dose of 7.5 g/day. PPI : proton
pump inhibitor.
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